Skip Navigation


International Immunology Advance Access originally published online on December 21, 2007
International Immunology 2008 20(2):259-266; doi:10.1093/intimm/dxm138
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/2/259    most recent
dxm138v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ashino, S.
Right arrow Articles by Nishimura, T.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ashino, S.
Right arrow Articles by Nishimura, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Japanese Society for Immunology. 2007. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific Th2-cell migration into lung

Shigeru Ashino1, Daiko Wakita1, Yue Zhang2, Kenji Chamoto1, Hidemitsu Kitamura1 and Takashi Nishimura1,2

1 Division of Immunoregulation, Institute for Genetic Medicine, Hokkaido University, Sapporo 060-0815, Japan
2 Division of ROYCE’ Health Bioscience, Institute for Genetic Medicine, Hokkaido University, Sapporo 001-0021, Japan

Correspondence to: T. Nishimura; E-mail: tak24{at}igm.hokudai.ac.jp

Allergic airway inflammation is one of the most typical characteristic features of bronchial asthma. Th2 cells, which produce IL-4, IL-5 and IL-13, are well known as major effector lymphocytes of the inflammation. In the present work, we found that subcutaneous injection of Toll-like receptor-9-ligand, CpG-oligodeoxynucleotides (CpG-ODN), remarkably suppressed eosinophilia and mucus hyper-production in Th2 cell-dependent airway inflammation model at the effector phase. The injection of CpG-ODN significantly blocked Th2 cell migration into lung. The inhibitory effects of CpG-ODN were observed even when IFN-{gamma}-deficient Th2 cells were transferred into IFN-{gamma}–/– mice. In contrast, the administration of neutralizing mAbs against type I cytokines such as IFN-{alpha}, IFN-β and IL-12 significantly suppressed the inhibitory effect of CpG-ODN on airway inflammation and Th2 cell migration into the lung. We further demonstrated that the production of Th2 chemokines, thymus and activation-regulated chemokine (TARC) and macrophage-derived chemokine (MDC), was significantly reduced by the CpG-ODN. The reduction of both TARC and MDC was also inhibited by the blockade of IFN-{alpha}, IFN-β and IL-12 with mAbs. Thus, we revealed here that IFN-{alpha}, IFN-β and IL-12, but not IFN-{gamma}, were required for the inhibitory effect of CpG-ODN in Th2 cell-mediated allergic airway inflammation. The present evidence strongly suggest that induction of type I cytokines would be promising therapeutic targets in Th2-dependent allergic diseases such as bronchial asthma.

Keywords: bronchial asthma, CpG-ODN, IL-12, Th2 chemokine, type I interferons

Transmitting editor: M. Miyasaka

Received 28 August 2007, accepted 22 November 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.